NCT07710105Recruiting
Ocrevus Zunovo for MS: Mixed Methods
Ocrevus Zunovo for Patients With Multiple Sclerosis: Mixed Methods on Barriers and Facilitators to Use and Retention
Source: ClinicalTrials.gov · Last updated 20 Jul 2026
Brief summary (registry, in English)
Ocrevus Zunovo implementation, feasibility, acceptability, patient satisfaction, treatment persistence, and impact on MS disease outcomes will be analyzed in this mixed methods study. This study will incorporate clinical data and questionnaire results from MS patients who take Ocrevus Zunovo as well as qualitative interviews with MS patients, family members, and other individuals involved in Ocrevus Zunovo treatment. The purpose of this study is to synthesize implementation strategies that improve patient access to high-efficacy MS therapies in real-world settings.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 13 Jul 2026
- Start date
- 12 Jun 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Northwestern University
- Diseases
- Multiple sclerosis
- NCT number
- NCT07710105
What you commit to
- Study type: Observational
- Planned participants: 150
- From 12 Jun 2026 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current participant in an MS or any experimental therapy clinical trial
- Currently taking a DMT that has not been washed out (e.g. recent treatment with Cladribine, Natalizumab, sphingosine 1-phosphate inhibitor, implying the last DMT is still actively immunosuppressing the patient)
- Current chemotherapy
- Prior allergic reaction or intolerance to Ocrelizumab IV or SubQ or any monoclonal antibody therapy
Other illness
- History of stem cell transplant, CAR-T or other chemo-ablative procedures
- Active hepatitis or latent hepatitis B
- Tuberculosis
- Current serious infection, e.g. COVID-19, shingles, active pneumonia, progressive multifocal leukoencephalopathy, etc.
Other
- Unclear diagnosis of MS
- Incarcerated
- Unable to provide informed consent
- Moribund
- Unable to speak a language for which consent processes are available at Northwestern Hospitals
- Unwilling to complete surveys over the course of the following 12 months
- No access to computer or telephone
- Hypogammaglobulinemia IgG level \<500
- Leukopenia \<2.0
- Elevated liver enzymes 3 times the upper limit of normal
- Currently pregnant, breastfeeding, or a person of childbearing capacity who is sexually active without a documented plan of current contraceptive methods.
- Any other diagnosis or reason deemed to make the participant unfit for participation by the study PI
Who the study is looking for
- Age of 18 years or older
- Resident of the USA
- Seen at Northwestern Medicine
- Meets diagnostic criteria (2024) for MS, either RMS or PPMS
- Diagnosis of MS (G35) on file by a neurologist
- Wants to start or restart a DMT for MS
- Willing to be in a 12-month follow up study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Northwestern Memorial Hospital Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.